Sort   by:  
 Page size 
ProteomicsMapping Ndc80 phosphorylation sites
Aurora A-TPX2 activity limits NDC80 phosphorylation
ORGANISM(S): Homo sapiens (Human) 
2023-03-06 | PXD038197 | Pride
Human Ndc80 Hela Kinetochore Ndc80 complex Phosphorylation Metaphase Aurora a Aurora b 
ProteomicsOrdered dephosphorylation initiated by the selective proteolysis of cyclin B drives mitotic exit
APC/C-mediated proteolysis of cyclin B and securin promotes entry into anaphase, inactivating CDK1 and permitting chromosome segregation, respectively. Reduction of CDK1 activity relieves inhibition of the CDK1-opposing phosphatases PP1 and PP2A-B55 leading to dephosphorylation of substrates crucial...
ORGANISM(S): Homo sapiens (Human) 
2020-09-04 | PXD019786 | Pride
Dephosphorylation Mitosis Phospho-proteomics Mitotic exit Cell cycle Pp1 Apcc 
ProteomicsOrdered dephosphorylation initiated by the selective proteolysis of cyclin B drives mitotic exit
APC/C-mediated proteolysis of cyclin B and securin promotes entry into anaphase, inactivating CDK1 and permitting chromosome segregation, respectively. Reduction of CDK1 activity relieves inhibition of the CDK1-opposing phosphatases PP1 and PP2A-B55 leading to dephosphorylation of substrates crucial...
ORGANISM(S): Homo sapiens (Human) 
2020-09-04 | PXD019787 | Pride
Dephosphorylation Mitotis Mitotic exit Cell cycle Apc/c 
ProteomicsOrdered dephosphorylation initiated by the selective proteolysis of cyclin B drives mitotic exit
APC/C-mediated proteolysis of cyclin B and securin promotes entry into anaphase, inactivating CDK1 and permitting chromosome segregation, respectively. Reduction of CDK1 activity relieves inhibition of the CDK1-opposing phosphatases PP1 and PP2A-B55 leading to dephosphorylation of substrates crucial...
ORGANISM(S): Homo sapiens (Human) 
2020-09-04 | PXD019791 | Pride
Proteomics Mitosis Mitotic exit Proteolysis Cell cycle Apc/c 
ProteomicsOrdered dephosphorylation initiated by the selective proteolysis of cyclin B drives mitotic exit
APC/C-mediated proteolysis of cyclin B and securin promotes entry into anaphase, inactivating CDK1 and permitting chromosome segregation, respectively. Reduction of CDK1 activity relieves inhibition of the CDK1-opposing phosphatases PP1 and PP2A-B55 leading to dephosphorylation of substrates crucial...
ORGANISM(S): Homo sapiens (Human) 
2020-09-04 | PXD019788 | Pride
Dephosphorylation Phospho-proteomics Mitotic exit Cell cycle Mitosis 
ProteomicsOrdered dephosphorylation initiated by the selective proteolysis of cyclin B drives mitotic exit
APC/C-mediated proteolysis of cyclin B and securin promotes entry into anaphase, inactivating CDK1 and permitting chromosome segregation, respectively. Reduction of CDK1 activity relieves inhibition of the CDK1-opposing phosphatases PP1 and PP2A-B55 leading to dephosphorylation of substrates crucial...
ORGANISM(S): Homo sapiens (Human) 
2020-09-04 | PXD019795 | Pride
Mitosis Mitotic exit Proteolysis Cell cycle Apc/c Proteome 
GenomicsStretch-Enhancers Delineate Disease-Associated Regulatory Nodes in T Cells
T Cell stretch-enhancers are vulnerable to Jak inhibitor tofacitinib Treatment of T cells with the Janus kinase (JAK) inhibitor, tofacitinib, disproportionately altered the expression of RA risk genes with stretech-enhancer (SE) structures.
ORGANISM(S): Homo sapiens 
2015-02-18 | E-GEOD-60482 | biostudies-arrayexpress
TranscriptomicsENCODE SUNY RNA Binding Protein Tiling Data for K562 and GM12878
RNA Binding Protein immunoprecipitation study for multiple target proteins in K562 & GM12878 cell lines as part of the ENCODE consortium. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2...
ORGANISM(S): Homo sapiens 
2012-09-24 | E-GEOD-40691 | biostudies-arrayexpress
UnknownOutcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
Not available
S-EPMC4766028 | biostudies-literature
UnknownOutcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
Not available
S-EPMC4306628 | biostudies-literature
Sort   by:  
 Page size